COVID-19: WHO Decision To Halt HCQ Trial Taken In Haste Says CSIR Director-General Shekhar Mande
DG CSIR stated that since there is a global outcry it must have put pressure on both Lancet as well as WHO and both of them now retracted from their original position.
CSIR Director-General Shekhar Mande said that the World Health Organisation’s decision to stop the trials of hydroxychloroquine (HCQ) drug was taken in haste and the global body should have analysed the data before drawing any decision. Dr Sheela Godbole, National Coordinator of the WHO-India Solidarity Trial and Head of the Division of Epidemiology, ICMR-National AIDS Research Institute also wrote a letter via an email to Dr Soumya Swaminathan, Chief Scientist at World Health Organisation.
In a letter, Dr Godbole stated: “There was no reason to suspend the trial for safety concern,” attributing it to the current RECOVERY data which differs significantly from the non-randomised assessment by Mehra et al, a scientific paper. (ANI)
Referring to the letter, the CSIR head said, “We don’t know what actually happened behind the scenes but the hypothesis is that because of the paper published in Lancet. It is a very well known journal and if Lancet has done due vigilance in publishing the paper. Therefore, the WHO thought the paper’s findings are right that’s why WHO hold based on what is published on Lancet. The WHO shouldn’t have accepted it immediately this should have taken their own due vigilance to find out that study is right or not.”
DG CSIR stated that since there is a global outcry it must have put pressure on both Lancet as well as WHO and both of them now retracted from their original position. “WHO has started a trial again and Lancet has put an expression of concern on their website. So I am pretty sure that Lancet would have published the reports only after seeing somewhere the drug failed to work,” Mande said.
Catch other news updates exclusively on ZEE5!